Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis

Inflammatory Bowel Diseases

Volumn 16, Issue 7, 2010, Pages 1180-1186

  Lukas, Milan ^a   Drastich, Pavel ^b   Konecny, Michal ^c   Gionchetti, Paolo ^d   Urban, Ondrej ^e   Cantoni, Franco ^f   Bortlik, Martin ^a   Duricova, Dana ^a   Bulitta, Michael ^g  

^a Thomaye s University Hospital   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e Vitkovicka nemocnice as   (Czech Republic)

^f SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^g CRM Biometrics GmbH   (Germany)

Author keywords

Alkaline phosphatase; Clinical trial; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CALGRANULIN; IMMUNOSUPPRESSIVE AGENT; STEROID;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; FEVER; FLATULENCE; HEADACHE; HUMAN; HYPOGLYCEMIA; INSOMNIA; MALE; ODYNOPHAGIA; PHARYNGITIS; PRIORITY JOURNAL; SIDE EFFECT; THRUSH; TREATMENT OUTCOME; ULCERATIVE COLITIS; VOMITING; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953698231     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21161     Document Type: Article

References (38)

1. Harris H. The human alkaline phosphatases: what we know and what we don't know. Clin Chim Acta. 1990;186:133-150.
2. Alkaline phosphatases. McComb RB, Bowers Jr GN, Posen S, eds. New York: Plenum Press; 1979.
3. O'Brien PJ, Herschlag D. Functional interrelationships in the alkaline phosphatase superfamily: phosphodiesterase activity of Escherichia coli alkaline phosphatase. Biochemistry. 2001;40:5691-5699.
4. Yang C, Kong J, Wang Q, et al. Heterosis of haemolymph analytes of two geographic populations in Chinese shrimp Fenneropenaeus chinensis. Fish Shellfish Immunol. 2007;23:62-70.
5. Millán JL. Alkaline phosphatases: structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signal. 2006;2:335-341.
6. Anon. Monograph Summary: EC 3.1.3.1: Alkaline phosphatase, of Phosphoric Monoester Hydrolases (EC 3.1.3), of Acting on Ester Bonds (EC 3.1), of Hydrolases (EC 3); IntEnz Enzyme Nomenclature. http://www.ebi.ac.uk/intenz/ query?cmd=SearchEC&ec=3.1.3.1
7. Stigbrand T, Millán JL, Fishman WH. The genetic basis of alkaline phosphatase isozyme expression. Isozymes Curr Top Biol Med Res. 1982;6:93-117.
8. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001;414:916-920.
9. Picher M, Burch LH, Hirsh AJ, et al. Ecto 5′-nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem. 2003;278:13468-13479.
10. Vaishnava S, Hooper LV. Alkaline phosphatase: keeping the peace at the gut epithelial surface. Cell Host Microbe. 2007;2:365-367. (Pubitemid 350215328)
11. Malo MS, Biswas S, Abedrapo MA, et al. The pro-inflammatory cytokines, IL-1beta and TNF-alpha, inhibit intestinal alkaline phosphatase gene expression. DNA Cell Biol. 2006;25:684-695.
12. Poelstra K, Bakker WW, Klok PA, et al. Dephosphorylation of endotoxin by alkaline phosphatase in vivo. Am J Pathol. 1997;151:1163-1169. (Pubitemid 27424326)
13. Poelstra K, Bakker WW, Klok PA, et al. A physiologic function for alkaline phosphatase: endotoxin detoxification. Lab Invest. 1997;76:319-327. (Pubitemid 27157340)
14. Bentala H, Verweij WR, Huizinga-Van der Vlag A, et al. Removal of phosphate from lipid a as a strategy to detoxify lipopolysaccharide. Shock 2002;18:561-566.
15. Beumer C, Wulferink M, Raaben W, et al. Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J Pharmacol Exp Ther. 2003;307:737-744.
16. Bates JM, Akerlund J, Mittge E, et al. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. Cell Host Microbe. 2007;2:371-382.
17. Domar U, Nilsson B, Baranov V, et al. Expression of intestinal alkaline phosphatase in human organs. Histochemistry. 1992;98:359-364.
18. Tuin A, Poelstra K, Jager-Krikken A, et al. Role of alkaline phosphatase in colitis in man and rats. Gut. 2009;58:379-382.
19. Pickkers P, Snellen F, Rogiers P, et al. Clinical pharmacology of exogenously administered alkaline phosphatase. Eur J Clin Pharmacol. 2009;65:393-402.
20. Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline Phosphatase treatment improves renal function in patients with severe sepsis or septic shock. Crit Care. 2007;11(suppl 2):P14. Abstract.
21. Tung CB, Tung CF, Yang DY, et al. Extremely high levels of alkaline phosphatase in adult patients as a manifestation of bacteremia. Hepatogastroenterology. 2005;52:1347-1350.
22. Maldonado O, Demasi R, Maldonado Y, et al. Extremely high levels of alkaline phosphatase in hospitalized patients. J Clin Gastroenterol. 1998;27:342-345.
23. Rojo OP, Roman ALS, Arbizu EA, et al. Serum lipopolysaccharidebinding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:269-277.
24. Amati L, Caradonna L, Leandro G, et al. Immune abnormalities and endotoxemia in patients with ulcerative colitis and in their first degree relatives: attempts at neutralizing endotoxin-mediated effects. Curr Pharm Des. 2003;9:1937-1945.
25. Caradonna L, Amati L, Magrone T, et al. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res. 2000;6:205-214.
26. Ramasamy S, Malo MS, Mostafa G, et al. A potential role for intestinal alkaline phosphatase in colonic inflammation. Gastroenterology. 2009;136(suppl 1): Poster Presentation, Abstract S1670. http://download.abstractcentral.com/ DDW2009/myddw2009/S1670.html
27. Chen K, Malo MS, Zeller S. Intestinal alkaline phosphatase protects against mucosal inury by commensal bacteria: elucidation of mechanism. Gastroenterology. 2009;136(suppl 1): Poster Presentation, Abstract T1856. http://download.abstractcentral.com/DDW2009/myddw2009/T1856.html
28. Anon. International Conference on Harmonization; Harmonized Tripartite Guideline; General Considerations for Clinical Trials; Section 2.0: General Principles; Subsection 2.2: Scientific Approach to Design and Analysis. http://www.ich.org/LOB/media/MEDIA484.pdf
29. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
30. European Medicines Agency. EMEA/CPMP/CVMP: note for guidance on minimizing the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMEA/410/01rev.2). http://www.emea. europa.eu/pdfs/human/bwp/TSE%20NGF%20410-rev2.pdf
31. Wulferink M, Brands R, Raaben W, et al. Pharmacokinetics and safety of BIAP administered as a single bolus in the duodenum, jejunum and ileum in piglets. AM-Pharma (internal) Preclinical Report: (2005) Study AP-IBD-PC003/004.
32. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462-2476. (Pubitemid 41770166)
33. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ. 1955;2:1041-1048.
34. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987;317:1625-1629.
35. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786.
36. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099-1105.
37. Anon. World Health Organization, International Conference on Harmonization Topic E6 Guideline for Good Clinical Practice. US Federal Register, Vol.62, No. 90, May 9, 1997:2561-2570E7. http://www.ich.org/LOB/media/ MEDIA482.pdf
38. Bours MJL, Swennen ERL, Di Virgilio F, et al. Adenosine 5′-triphosphate and adenosine as endogenous signalling molecules in immunity and inflammation. Pharmacol Ther. 2006;112:358-404.